New insights and results from the RE-LY trial

被引：0
|
作者：
不详
机构：
来源：
CARDIOVASCULAR JOURNAL OF AFRICA | 2011年 / 22卷 / 05期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; WARFARIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：284 / 286
页数：2
相关论文
共 50 条
  • [31] Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials
    Aulin, Julia
    Hijazi, Ziad
    Siegbahn, Agneta
    Andersson, Ulrika
    Alexander, John H.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Gersh, Bernard J.
    Granger, Christopher B.
    Horowitz, John
    Hylek, Elaine M.
    Lopes, Renato D.
    Yusuf, Salim
    Wallentin, Lars
    Oldgren, Jonas
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2287 - 2295
  • [32] Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation
    Webster-Clark, Michael
    Lund, Jennifer L.
    Sturmer, Til
    Poole, Charles
    Simpson, Ross J.
    Edwards, Jessie K.
    EPIDEMIOLOGY, 2020, 31 (05) : 605 - 613
  • [33] Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)
    Millenaar, Dominic
    Schumacher, Helmut
    Brueckmann, Martina
    Eikelboom, John W.
    Ezekowitz, Michael
    Slawik, Jonathan
    Ewen, Sebastian
    Ukena, Christian
    Wallentin, Lars
    Connolly, Stuart
    Yusuf, Salim
    Bohm, Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 149 : 27 - 35
  • [34] What are the emerging therapeutic alternatives to Warfarin in Stroke patients? How would the results of RE-LY benefit Pakistanis?
    Khan, Maria
    Raza, Emmon
    Kamal, Ayeesha Kamran
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2011, 61 (06) : 612 - 613
  • [35] Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure Substudy of the RE-LY trial
    Douketis, James D.
    Healey, Jeff S.
    Brueckmann, Martina
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Fraessdorf, Mandy
    Noack, Herbert
    Oldgren, Jonas
    Reilly, Paul
    Spyropoulos, Alex C.
    Wallentin, Lars
    Connolly, Stuart J.
    THROMBOSIS AND HAEMOSTASIS, 2015, 113 (03) : 625 - 632
  • [36] Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
    Hijazi, Ziad
    Verdecchia, Paolo
    Oldgren, Jonas
    Andersson, Ulrika
    Reboldi, Gianpaolo
    Di Pasquale, Giuseppe
    Mazzotta, Giovanni
    Angeli, Fabio
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Yusuf, Salim
    Wallentin, Lars
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (02):
  • [37] Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
    Healey, Jeff S.
    Eikelboom, John
    Douketis, James
    Wallentin, Lars
    Oldgren, Jonas
    Yang, Sean
    Themeles, Ellison
    Heidbuchle, Hein
    Avezum, Alvaro
    Reilly, Paul
    Connolly, Stuart J.
    Yusuf, Salim
    Ezekowitz, Michael
    CIRCULATION, 2012, 126 (03) : 343 - 348
  • [38] Is Dabigatran is the ideal antithrombotic drug? Commentary on the RE-LY study
    Gaciong, Zbigniew
    KARDIOLOGIA POLSKA, 2009, 67 (10) : 1153 - 1154
  • [39] Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial
    Le Heuzey, Jean-Yves
    Marijon, Eloi
    Connolly, Stuart
    Brueckmann, Martina
    Yang, Sean
    Pogue, Janice
    Eikelboom, John
    Ezekowitz, Michael
    Themeles, Ellison
    Wallentin, Lars
    Yusuf, Salim
    STROKE, 2013, 44 (02)
  • [40] Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary
    Waks, Jonathan W.
    Zimetbaum, Peter J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (11) : 1461 - 1471
12345